

**FORM 51-102F3  
MATERIAL CHANGE REPORT  
UNDER NATIONAL INSTRUMENT 51-102**

**Item 1           Name and Address of Company**

Abattis Bioceuticals Corp. (the “**Issuer**”)  
104 - 9295 198th Street,  
Langley, B.C., V1M 3J9

**Item 2           Date of Material Change**

March 13, 2017

**Item 3           News Release**

A news release was disseminated on March 13, 2017 through the facilities of NewsFile and subsequently filed on SEDAR.

**Item 4           Summary of Material Change**

On March 13, 2017 the Issuer announced the addition of Jaclyn Thomson, PhD, to the senior management team at Northern Vine Labs and the appointment of Rene David to the Abattis Board of Directors. As the construction and buildout of Northern Vine Labs continues, more key management hires and appointments will accompany this next stage of growth.

**Item 5           Full Description of Material Change**

On March 13, 2017 the Issuer announced the addition of Jaclyn Thomson, PhD, to the senior management team at Northern Vine Labs and the appointment of Rene David to the Abattis Board of Directors. As the construction and buildout of Northern Vine Labs continues, more key management hires and appointments will accompany this next stage of growth.

Jaclyn will join the team, and will be responsible for lab operations and testing protocols while ensuring all transactions involving controlled substances comply with appropriate regulations and standards.

Jaclyn obtained her BSc. At the University of Victoria and her PhD. in Organometallic Chemistry from the University of British Columbia. She brings a wide breadth of experience to the Company involving her previous positions in Quality Assurance, Scientific and Regulatory Consultation and Research. Jaclyn has years of experience in lab operations and is credited with publishing a highly successful academic manuscript regarding the extensive worldwide problem of Ginko Biloba adulteration in the journal Phyto-medicine. Management feels confident that Jaclyn will be a key leader in Northern Vine’s efforts to test for licensed producers and patients under the ACMPR system.

“Her appointment is a critical component of our overall strategy to position Northern Vine as the leader in not only the testing of, but also the subsequent formulations and science behind the cannabis plant”, says Rene David, CFO of Abattis. “Jaclyn’s in-depth knowledge of GMP as well as natural health products and Health Canada regulations means Northern Vine will maintain consistency with its procedures and ensure safe and reliable results on every product tested.”

The shift of Mr. David from day-to-day operations into a position of oversight, signals the lengthy preparations the Company has made to harness and sustain a focused growth trajectory. As CFO of Abattis, Mr. David has gained tremendous experience in the medical cannabis industry through working with Abattis and has been instrumental in guiding the Company's strategic expansion.

Jim Irving, director welcomes Mr. David to the Board: "We are happy to have Rene join the Board. His experience as CFO and COO will provide us with valuable insight and practical solutions, to move the Company forward in the dynamic legal cannabis and nutraceutical industries in Canada and abroad."

Mr. David has over 20 years of experience in real estate development, finance, and business strategy. He started his career at Vancity, Canada's largest Credit Union as a real estate developer and then went into investment banking in Western Canada. He later expanded his interests to include the resource, food and water industries, and assisting corporations who are dealing with the globalization of local re-sources. In his normal course of duties, Mr. David's responsibilities include internal financial controls and analysis, procurement and contracts management. His continuous review of operating and capital plans is geared towards improving the internal controls and financial best practices in order to deliver highest value product and strong company values.

Mr. David noted: "Since receiving our Health Canada Dealers License in September of 2016, we have narrowed our focus on key pillars for future growth: testing and analytics; and, product sales into international markets through its wholly owned subsidiary, Vergence Bioceuticals. As we prepare Northern Vine Labs for the next stage of operations, I felt it was appropriate to transition to the position of director and open up the leadership program to a greater level. A lot of hard work has been completed and I am excited to see what the Abattis team will bring as the Company moves into a stage of growth."

**Item 6            Reliance on subsection 7.1(2) of National Instrument 51-102**

N/A

**Item 7            Omitted Information**

N/A

**Item 8            Executive Officer**

*"Rene David"*

Rene David

CFO

Abattis Bioceuticals Corp.

Tel: 604.336.0881

**Item 9            Date of Report**

March 17, 2017

**Cautionary Note Regarding Forward Looking Statements**

*This material change report contains certain forward-looking statements about the Company's future plans and intentions, including statements relating to the Company's intention to implement changes across its business to achieve growth. Wherever possible, words such as "may", "will", "should", "could", "expect", "plan", "intend", "anticipate", "believe", "estimate", "predict", "scheduled" or "potential" or the negative or other variations of these*

*words, or similar words or phrases, have been used to identify these forward-looking statements. These statements reflect Management's current beliefs and are based on information currently available to management as at the date hereof.*

*Forward-looking statements involve significant risk, uncertainties and assumptions. Many factors could cause actual results, performance or achievements to differ materially from the results discussed or implied in the forward-looking statements. These factors should be considered carefully and readers should not place undue reliance on the forward looking statements. Although the forward-looking statements contained in this press release are based upon what management believes to be reasonable assumptions, the Company cannot assure readers that actual results will be consistent with these forward-looking statements. These forward-looking statements are made as of the date of this press release, and the Company assumes no obligation to update or revise them to reflect new events or circumstances, except as required by law.*